Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- Sacubitril/valsartan (Entresto) was effective at keeping cardiotoxicity at bay in high-risk people receiving ...
China: A recent cohort study has suggested that sacubitril/valsartan may offer superior kidney function benefits for patients ...
Sacubitril-valsartan, a common drug combination for heart failure, cuts the risk for cardiomyopathy after chemotherapy in patients who received anthracycline drugs by 77% in the first randomized ...
Sacubitril/valsartan reduced cardiomyopathy risk by 77% in cancer patients on anthracycline chemotherapy, as shown in the SARAH trial. The trial involved 114 adults, primarily women with breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback